uniQure N.V.

NASDAQ (USD): uniQure N.V. (QURE)

Last Price

14.35

Today's Change

-0.95 (6.20%)

Day's Change

14.21 - 15.20

Trading Volume

576,164

Overview

Market Cap

845 Million

Shares Outstanding

48 Million

Avg Volume

2,060,761

Avg Price (50 Days)

8.35

Avg Price (200 Days)

6.30

PE Ratio

-3.51

EPS

-4.95

Earnings Announcement

24-Feb-2025

Previous Close

17.43

Open

17.67

Day's Range

16.81 - 18.12

Year Range

3.73 - 18.12

Trading Volume

427,107

Price Change Highlight

1 Day Change

-0.46%

5 Day Change

11.36%

1 Month Change

186.78%

3 Month Change

249.09%

6 Month Change

294.32%

Ytd Change

150.36%

1 Year Change

147.86%

3 Year Change

-19.23%

5 Year Change

-76.75%

10 Year Change

15.90%

Max Change

18.75%

News and Blogs
Latest Hottest Following

No result.

Company Profile

Sector: Healthcare - Healthcare

Industry: Biotechnology

Description:

uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-210, a product candidate for the treatment of Parkinson's disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical product candidate for the treatment of autosomal dominant Alzheimer's disease; and AMT-161 for the treatment of amyotrophic lateral sclerosis. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment